Showing results (61-70 of 152) with videos related to
Sort By:
Pageof 16
Gastroenterology|February 15, 2017
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated AnalysisIra M Jacobson, Eric Lawitz, Paul Y Kwo, et al.Journal of Clinical Pharmacology|December 31, 2013
Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairmentThomas Marbury, Eric Lawitz, Robert Stonerock, et al.The Lancet. Gastroenterology & Hepatology|March 19, 2023
Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trialRohit Loomba, Manal F Abdelmalek, Matthew J Armstrong, et al.The New England Journal of Medicine|January 4, 2013
Exploratory study of oral combination antiviral therapy for hepatitis CFred Poordad, Eric Lawitz, Kris V Kowdley, et al.Annals of the New York Academy of Sciences|August 4, 2015
Development of sofosbuvir for the treatment of hepatitis C virus infectionEric Lawitz, Ira M Jacobson, David R Nelson, et al.Hepatology (Baltimore, Md.)|May 1, 2026
Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trialNaga Chalasani, Raj Vuppalanchi, Mazen Noureddin, et al.Journal of Hepatology|November 5, 2022
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASHVlad Ratziu, Stephen A Harrison, Véronique Loustaud-Ratti, et al.Gastroenterology|July 15, 2015
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without CirrhosisEric Lawitz, Mihály Makara, Ulus Salih Akarca, et al.Clinical Pharmacokinetics|March 27, 2025
Pharmacokinetics and Safety of Navitoclax in Hepatic ImpairmentMaulik Patel, Jalaja Potluri, Thomas Marbury, et al.Journal of Hepatology|December 8, 2016
Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvirDavid Wyles, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.Pageof 16